Press Releases

Nov 23, 2016
BeiGene Announces Closing of $200 Million Public Offering    read more...
Nov 17, 2016
BeiGene Announces Pricing of $200 Million Public Offering    read more...
Nov 16, 2016
BeiGene Announces Proposed Public Offering    read more...
Nov 11, 2016
BeiGene Presents Updated Clinical Data on PD-1 Antibody BGB-A317 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 31st Annual Meeting    read more...
Nov 10, 2016
BeiGene Reports Third Quarter 2016 Financial Results    read more...
Nov 03, 2016
BeiGene Announces Oral Presentations on BTK Inhibitor BGB-3111 at the 2016 American Society of Hematology Annual Meeting    read more...
Nov 01, 2016
BeiGene to Participate in 25th Annual Credit Suisse Healthcare Conference    read more...
Oct 07, 2016
BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenstrom’s Macroglobulinemia at 9th International Workshop on Waldenstrom’s Macroglobulinemia    read more...
Oct 04, 2016
BeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9    read more...
Oct 03, 2016
BeiGene Appoints Ross Pettit as Senior Vice President, Global Development Operations    read more...
Sep 11, 2016
BeiGene Receives Approval to Initiate Clinical Trials in China with PD-1 Antibody BGB-A317    read more...
Sep 06, 2016
BeiGene Appoints Jane Huang, M.D. as Chief Medical Officer, Hematology    read more...
Aug 31, 2016
BeiGene to Participate in Baird and Morgan Stanley Global Healthcare Conferences    read more...
Aug 24, 2016
BeiGene Appoints Amy Peterson, M.D. as Chief Medical Officer, Immuno-oncology    read more...
Aug 18, 2016
BeiGene Receives Approval to Initiate Clinical Trials in China with PARP Inhibitor BGB-290    read more...
Aug 10, 2016
BeiGene Reports Second Quarter 2016 Financial Results    read more...
Jul 05, 2016
BeiGene Announces First Patient Dosing for Investigational BTK Inhibitor BGB-3111 in China    read more...
Jun 29, 2016
BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317    read more...
Jun 06, 2016
BeiGene to Participate in Goldman Sachs 37th Annual Global Healthcare Conference    read more...
Jun 05, 2016
BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting    read more...